Newpath Partners
Venture capitalActively deployingBoston · Seed–Series A · 3 people tracked
Also known as NEWPATH MANAGEMENT, L.P.
Investment thesis
Led by physician-scientist Tom Cahill, they form companies from academic discoveries in gene editing and regenerative medicine, offering company-formation expertise, board experience, and a high formation-and-exit track record.
Source: firm website, verified Jul 28, 2026.
Team · 3 people
from public directories
What they invest in
from 17 of 19 portfolio companiesBiotech ×14Medical Devices ×14Healthtech ×6Deep Tech ×5AI & Machine Learning ×3Digital Health ×3Travel & Hospitality ×1
HQs:United States×8
Investments · 19 tracked
founders shown can be your intro pathNeumora is a clinical research company developing investigational medications, with a focus on conducting clinical trials to obtain regulatory approval and make treatments available to patients.
BiotechDeep TechDigital HealthMedical DevicesWatertown, US
Kristina Burow(Director)Matthew Fust(Director)Robert Nelsen(Director)Kari Stefansson(Director)Paul Berns(Executive Officer, Director)Stacie Weninger(Director)
Prime Medicine develops Prime Editing, a gene editing platform designed to correct disease-causing mutations in the human genome.
BiotechHealthtechMedical Devices
Exo Therapeutics is a small molecule drug discovery company developing therapeutics through its ExoSight platform, which targets exosites—unique binding pockets on enzymes—to address previously undruggable diseases in oncology, inflammation, and other therapeutic areas.
BiotechDeep TechMedical Devices
David Liu, PhD(Founder)Alan Saghatelian, PhD(Co-Founder)David LiuAlan Saghetelian
Magnet Biomedicine develops TrueGlue™, a molecular glue discovery platform for designing small molecule therapeutics that induce novel protein-protein interactions to treat cancer and immune disorders.
AI & Machine LearningBiotechMedical Devices
Benjamin F. Cravatt, PhD(Founder & Advisor)David A. Spiegel, MD, PhD(Founder & Advisor)Michael Rosbash, PhD(Founder & Advisor)Richa Saxena, PhD(Founder & Advisor)Stuart Schreiber, PhD(Founder & Advisor)
nChroma Bio develops in vivo targeted delivery and genetic engineering technologies for genetic medicine applications.
BiotechDeep TechMedical Devices
Luke Gilbert, PhDKeith Joung, MD, PhDDavid Liu, PhDAngelo Lombardo, PhDLuigi Naldini, MD, PhDJonathan Weissman, PhD
Autobahn develops medicines for central nervous system (CNS) disorders by leveraging regenerative mechanisms of the human body.
BiotechDeep TechMedical DevicesSan Diego, US
Kevin Finney(Chairman, President and CEO)John Borkholder(Executive Officer)
BoardKristina Burow(Director)Timothy Anderson(Director)Philip J DeSouza(Director)
Board seatThomas Cahill· per SEC Form D
Travel & HospitalityHouston, US
Andrew C. Levy(Chief Executive Officer)Hunter Keay(Chief Financial Officer)Robert Ashcroft(Director)Miguel Heras(Director)
BoardWill Snellings(Director)Thomas Mahr(Director)
Board seatThomas Cahill· per SEC Form D · $40M raise · filed Jan 2025
Boston, US
Board seatThomas Cahill· per SEC Form D · $135M raise · filed Sep 2023
DermBiont develops SM-030, a topical drug candidate targeting melasma, a skin pigmentation disorder, by inhibiting PKC-beta to address the underlying cause of hyperpigmentation.
BiotechDigital HealthMedical DevicesBoston, US
Karl R. Beutner(Executive Officer, Director)Nichola Eliovits(Executive Officer, Director)Max Dawson(Executive Officer)Jennifer Lee(Director)Robert Brucker(Executive Officer)
BoardWilder Ramsey(Director)
Board seatDaniel Yadegar· per SEC Form D · $45.3M raise · filed Nov 2024
BiotechBoston, US
Nagesh Mahanthappa, Ph.D.(Director)Amir Nashat, Ph.D.(Treasurer and Secretary)Susan Langer(President)Luba Greenwood(Director)
Board seatThomas J. Cahill· per SEC Form D · $60.2M raise · filed Jun 2021
BiotechBoston, US
Nichola Eliovits(Executive Officer, Director)Max Dawson(Executive Officer)Daniel Yadegar(Director)Karl Beutner(Executive Officer, Director)
Board seatDaniel Yadegar· per SEC Form D · $2.5M raise · filed Oct 2025
Aera Therapeutics develops genetic medicines using next-generation delivery technologies and precision payloads optimized for specific diseases.
AI & Machine LearningBiotechDeep TechMedical Devices
Akin Akinc, Ph.D.(CEO)
CREATE Medicines is a clinical-stage biotech company that develops in vivo mRNA immune cell programming therapies.
BiotechDigital HealthHealthtechMedical DevicesSan Francisco, US
Daniel Getts(Founder and CEO)inBrett Kaplan(Chief Financial and Business Officer)inMarcus Lowe(Executive Officer, Director)Dhruv Amin(Executive Officer, Director)
CREATE Medicines develops in vivo CAR immunotherapy using proprietary mRNA-LNP technology to program T cells, NK cells, and myeloid cells directly within the body for cancer, autoimmunity, and fibrosis.
AI & Machine LearningBiotechHealthtechMedical Devices
A pharmaceutical company developing therapeutics across oncology, hematology, neuroscience, immunology, and cardiovascular disease with a pipeline of 50 compounds targeting 40+ disease areas.
BiotechHealthtechMedical Devices
Rows marked “SEC filing” are inferred from directors named on the company's SEC Form D — public regulatory data, not a portfolio list published by the firm.
Frequently asked questions
- What stage does Newpath Partners invest at?
- Newpath Partners invests at the Seed, Series A stages.
- What is Newpath Partners's typical check size?
- Newpath Partners typically writes checks of $50K – $10M.
- What sectors does Newpath Partners focus on?
- Newpath Partners focuses on Biotech, Medical Devices.
- Where is Newpath Partners located?
- Newpath Partners is headquartered in Boston, US.
- Does Newpath Partners lead rounds?
- Newpath Partners typically participates in rounds rather than leading them.
Images
Similar investors
ACT Venture Capital is an independent Irish venture capital firm that invests €1 million to €15 million in growth-stage private companies, with capacity for larger commitments through syndicated rounds.
Amadeus Capital Partners is a UK-based deep tech venture capital firm founded in 1997 that invests from seed to growth stages across artificial intelligence, health, and sustainability-focused technologies.
B Capital Group is a global venture capital firm that backs founders from early to late stage, with dedicated stage-based funds and a portfolio spanning technology, healthcare, and energy and resilience sectors.
Breyer Capital is a venture capital firm that backs high-impact entrepreneurs, making strategic investments guided by founder passion and its network of experienced investors.
Capricorn Venture Partners is a European investment firm managing several thematic funds across growth capital, healthcare, and cleantech, as well as a combined private/quoted investment vehicle.